Eupraxia Pharmaceuticals Inc. (TSX:EPRX)
Canada · Delayed Price · Currency is CAD 11.04
-0.33 (-2.90%)
Mar 3, 2026, 4:00 PM EST
Eupraxia Pharmaceuticals Employees
Eupraxia Pharmaceuticals had 33 employees as of December 31, 2024. The number of employees increased by 4 or 13.79% compared to the previous year.
Employees
33
Change (1Y)
4
Growth (1Y)
13.79%
Revenue / Employee
n/a
Profits / Employee
-1.34M CAD
Market Cap
663.79M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 33 | 4 | 13.79% | 33 | 0 |
| Dec 31, 2023 | 29 | 8 | 38.10% | 29 | 0 |
| Dec 31, 2022 | 21 | 0 | - | 21 | 0 |
| Dec 31, 2021 | 21 | 9 | 75.00% | 19 | 2 |
| Dec 31, 2019 | 12 | 0 | - | 12 | 0 |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Bright Minds Biosciences | 26 |
| Medicenna Therapeutics | 18 |
| Satellos Bioscience | 17 |
| Devonian Health Group | 11 |
| Sernova Biotherapeutics | 8 |
| Helix BioPharma | 7 |
Eupraxia Pharmaceuticals News
- 11 days ago - Eupraxia Pharmaceuticals Announces Closing of US$63.2 Million Public Offering Including Full Exercise of Underwriter Option - GlobeNewsWire
- 13 days ago - Eupraxia Pharmaceuticals Announces Pricing of US$55 Million Public Offering of Common Shares and Pre-Funded Warrants - GlobeNewsWire
- 13 days ago - Eupraxia Pharmaceuticals Announces Proposed Public Offering - GlobeNewsWire
- 7 weeks ago - Eupraxia Pharmaceuticals Reports Positive Tissue Health Data from its Ongoing RESOLVE Trial in Eosinophilic Esophagitis Demonstrating Near-Complete Improvement on Biopsy - GlobeNewsWire
- 3 months ago - Eupraxia Pharmaceuticals Reports Additional 52-week Follow-up Data from the RESOLVE Trial in Eosinophilic Esophagitis (EoE) Demonstrating Consistent Results after Dosing with EP-104GI - GlobeNewsWire
- 4 months ago - Eupraxia Pharmaceuticals Reports Third Quarter 2025 Financial Results - GlobeNewsWire
- 5 months ago - Eupraxia Pharmaceuticals Announces Positive Data from Highest-Dose Cohort in the Ongoing RESOLVE Trial in Eosinophilic Esophagitis, and Plans for Expansion of EP-104GI Development Programs - GlobeNewsWire
- 5 months ago - Eupraxia Pharmaceuticals Announces Closing of US$80.5 Million Public Offering Including Full Exercise of Underwriter Option - GlobeNewsWire